



AGENDA

Pharmacy and Therapeutics Committee

April 29, 2019 12:00pm -5:00 pm
Gold Room, 3rd Floor
701 E. Jefferson Phoenix, AZ 85034

Teleconference: 1-240-454-0879 Passcode: 800 766 389

Agenda Topics

12:00 PM

Welcome and Introductions: Sara Salek, MD, Chief Medical Officer, AHCCCS

- July 17, 2018 P&T Minutes Review and Vote
- P&T Operational Policy Update
- Conflict of Interest Statement

12:15PM

Non-Supplemental Rebate Class Review:

1. Antidepressants, Other
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
2. Antidepressants, SSRIs
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
3. Bronchodilators, Beta Agonists
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
4. Bone Resorption Suppression and Related Agents
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony: None
5. Colony Stimulating Factors
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
6. Enzyme Replacement for Gaucher's Disease
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
7. Erythropoiesis Stimulating Proteins
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
8. Hypoglycemics, Alpha-Glucosidase Inhibitors
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
9. Hypoglycemics – Metformins
 - a. Clinical review: Hind Douiki, PharmD - Magellan
 - b. Public Testimony:
10. Hypoglycemics – SGLT2s

	<p>a. Clinical review: Hind Douiki, PharmD- Magellan b. Public Testimony:</p> <p>11. Immune Globulins a. Clinical review: Hind Douiki, PharmD - Magellan b. Public Testimony:</p> <p>12. Oncology, Oral-Hematologic a. Clinical review: Hind Douiki, PharmD - Magellan b. Public Testimony:</p> <p>13. Ophthalmic – Anti-Inflammatories / Immunomodulators a. Clinical review: Hind Douiki, PharmD - Magellan b. Public Testimony:</p> <p>14. Otic Antibiotics a. Clinical review: Hind Douiki, PharmD - Magellan b. Public Testimony:</p> <p>15. PAH Agents, Oral and Inhaled a. Clinical review: Hind Douiki, PharmD - Magellan b. Public Testimony:</p> <p>16. Thrombopoiesis Stimulating Proteins a. Clinical review: Hind Douiki, PharmD - Magellan b. Public Testimony:</p>
3:00 PM	Break
3:15 PM	Executive Session
4:15 PM	Public Therapeutic Class Votes
4:45 PM	Butalbital/APAP/Caffeine Tablets and Capsules FDA Daily Maximum Dosage – 6 capsules per day
	Biosimilar Update: None
	New Drug Reviews: None
5:00 PM	Meeting Adjournment

2019 Meeting Dates:

- **May 23, 2019**
- **October 15, 2019**

2020 Meeting Dates

- **January 22, 2020**
- **May 19 & 20, 2020**
- **October 14, 2020**